ABBV · Q2 2025 Earnings
BullishAbbVie
Reported July 31, 2025
30-second summary
Revenue grew 6.6% YoY to $15.42B with adjusted EPS of $2.97, and management raised FY2025 guidance for the second time this year — revenue up $800M to ~$60.5B and EPS up $0.21 to $11.88–$12.08. Skyrizi (+62.2%) and Rinvoc (+41.8%) combined for $6.45B in the quarter, already running ahead of the trajectory needed to offset Humira's -58.1% collapse to $1.18B. The tone shift is the most important signal: management is now committing to a "clear line of sight" for growth over the next eight years, language that breaks from AbbVie's historically defensive cadence around the Humira LOE.
Headline numbers
EPS
Q2 FY2025
$2.97
Revenue
Q2 FY2025
$15.42B
+6.6% YoY
Gross margin
Q2 FY2025
71.8%
Operating margin
Q2 FY2025
31.7%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $15.42B | +6.6% |
| EPS | $2.97 | — |
| Gross margin | 71.8% | — |
| Operating margin | 31.7% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Immunology | $7.631B | +9.5% |
| Skyrizi | $4.423B | +62.2% |
| Rinvoq | $2.028B | +41.8% |
| Humira | $1.18B | -58.1% |
| Neuroscience | $2.683B | +24.2% |
| Oncology | $1.676B | +2.6% |
| Aesthetics | $1.279B | -8.1% |
| Eye Care | $0.514B | -3.9% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted Gross Margin | 84.4% |
| Adjusted Operating Margin | 44.3% |
| Adjusted Diluted EPS | $2.97 |
| Adjusted SG&A as % of Revenue | 21.0% |
| Adjusted R&D as % of Revenue | 13.7% |
| Acquired IPR&D and Milestones Expense | $823M (5.3% of revenue) |
| U.S. Net Revenues Growth | 5.9% reported / 5.9% operational |
| International Net Revenues Growth | 9.1% reported / 8.4% operational |
Management tone
Management opened with "ABBV delivered another outstanding quarter, with results exceeding our expectations" — a notably forward-leaning posture for a company that has historically led with Humira-LOE caveats. The "vs. typical" read is that AbbVie is no longer talking like a company managing through a patent cliff; it is talking like a company that has cleared one.
The Skyrizi narrative escalated from "continued share gains" to category dominance. Management quantified that they are capturing "more than a third of new or switching patients in Crohn's disease" and are "on track to double sales this year" in IBD — the kind of share metric usually reserved for early-launch winners, not a drug now generating $4.4B per quarter. The accompanying $600M FY revenue raise on Skyrizi alone validates the framing.
Rinvoq's positioning expanded materially. Management called the alopecia areata data "truly transformative" and explicitly contrasted Rinvoc's placebo-adjusted SALT scores as "approximately 20 percentage points above the rates for the highest approved doses of other JAK inhibitors." In Q&A, the company quantified the next wave of indications (GCA, lupus, alopecia areata) as "approximately $2 billion to peak year sales" — converting what was previously a pipeline narrative into a sized commercial opportunity.
Oncology shifted from defensive to constructive. Imbruvica's decline narrative is now offset by ADC platform progress: TMAB-A showed "an objective response rate of 63% and median duration of response of 9.8 months" at ASCO, and the FY Imbruvica guide was raised $100M. The company is now talking about oncology as pipeline depth rather than a problem segment.
The standout phrase was the eight-year visibility claim: "we have a clear line of sight based on the portfolio we have today to drive that growth over the next eight years." Pharma management teams rarely commit to decade-scale growth visibility without invoking pipeline-dependent caveats; doing so here, paired with 30+ BD transactions since early 2024 (Gubra amylin, Capstan in-vivo CAR-T, ISB 2001 trispecific), signals that management views the next-leg growth profile as already de-risked at the asset level.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Vamo Devon · Guggenheim Securities
Can you quantify the commercial opportunity for RINVOKE in alopecia areata and its potential impact on RINVOKE sales? Also, what is management observing on the ground in aesthetic practices regarding macro impacts and patient flow trends?
Management highlighted impressive alopecia areata data with notable hair recovery compared to other JAK inhibitors. Positioned as the third wave of RINVOKE indications (after rheumatology and atopic dermatitis/IBD). The collection of next-wave indications (GCA, lupus, alopecia areata, etc.) expected to add approximately $2 billion to peak year sales. Regarding aesthetics, management noted stability with key headwinds in dermal filler market decline across major territories, patient price sensitivity, and sentiment concerns about overfilling. Plans substantial second-half work with clinicians and trainers to educate on natural results.
Steve Schaller · TD Cowan
How is current economic uncertainty different from past periods? Is competition also impacting aesthetic franchises? What is the status of AVI anti-amyloid monoclonal antibody and could it go directly to registrational trial based on imaging endpoint?
Management characterized current economic headwinds as more chronic and longer-lasting than past recessionary issues, with broader consumer pocketbook impact reflected in luxury goods trends. Attributed aesthetic softness to three factors: chronic consumer wallet constraints, sentiment shift toward natural look/overfilling concerns, and filler market-specific dynamics. Positioned upcoming short-acting toxin (trentenobot E) as disruptive innovation to drive recovery. On Alzheimer's: AVI-916 data similar to marketed comparators; company acquired Alieata technology with pyroglutamated amyloid targeting, BBB-crossing transferrin receptor tech, and long half-life. Planning subcutaneous delivery next year. Will pursue Phase 3 with both imaging and cognition endpoints rather than imaging-only registration.
Chong Wen · UBS
Why does Skyrizi 2Q sales suggest favorable pricing when guidance indicates low single-digit price concessions? What portion of Skyrizi sales comes from IBD induction, and is 1H pricing performance consistent with full-year expectations or should we expect pricing deterioration in H2?
Management confirmed 1H pricing favorability but attributed it to one-time items: unique price gating items and lighter-than-expected Part D redesign impact concentrated in back half of year. Explained 10-point differential between IQ prescription data and actual volume from induction gap. Clarified that overall pricing expected to be neutral for full year 2024, with negative pricing pressure anticipated in H2 as Part D headwinds materialize. This aligns with long-term low single-digit price concession guidance.
Gary Nachman · Raymond James
What competitive dynamics are emerging in IL-23 class with J&J's Tremfya IBD approvals and is there sufficient headroom in IBD market? Is Neuro strong growth volume-driven? Any changes to gross-net dynamics worth noting?
Management expressed confidence in Skyrizi competitive position based on dosing, convenience, and safety profile. Emphasized market expansion potential: IL-23 launches (Skyrizi and Tremfya) currently at single-digit patient share capture, versus 60% penetration achieved in psoriasis post-2018/2019. Affirmed ample headroom for multiple competitors while expecting Skyrizi to perform well with prudent share allocation to Tremfya. Confirmed Neuro growth predominantly volume-driven across all therapeutic segments (migraine leadership: #1 acute, #1 prevention, #1 chronic injector). Noted slight price benefit from Brelar due to Part D redesign impact but characterized as minimal versus volume growth.
Asad Hayter · Goldman Sachs
What are updated thoughts on the PD-1/VEGF combination class landscape and how is AbbVie positioned? What would it take for AbbVie to make a strategic move in this space?
Management indicated active monitoring of PD-1/VEGF class with multiple assets revealing data. Expressed interest contingent on partnership potential with internal ADC platform. Outlined strategic criteria: identification of good targets with high tumor expression versus healthy tissue expression to enable biomarker-based patient selection. Highlighted differentiation of proprietary linker technology and Topo warhead showing very low incidence of alopecia, stomatitis, diarrhea versus standard chemotherapy and other ADCs. Indicated openness to partnership assets combinable with multiple indications if safety/tolerability profile aligns with ADC platform strengths.
What to watch into next quarter
Whether Skyrizi can sustain the $4.4B+ quarterly run-rate that the new $17.1B FY guide implies — i.e., does Q3 land at or above $4.4B, or does the IBD induction-script tailwind unwind faster than expected.
Q3 pricing dynamics: management telegraphed H2 pricing turns negative as Part D redesign hits. Watch whether the Q3 print confirms the magnitude management has guided to or surprises in either direction.
Aesthetics inflection: is the -8.1% YoY the floor, or does the category deteriorate further into the back half before trenibotulinumtoxinE launches? Watch whether Botox Cosmetic + Juvederm growth turns less negative sequentially.
Humira US trajectory: $3.0B FY guide implies meaningful further deceleration in H2. Watch the Q3 Humira print to gauge whether the LOE curve is steeper than the new guide or whether the cut already over-reserved.
Rinvoc alopecia areata launch readiness and any incremental indication news (GCA approval, lupus data) — these are the building blocks of the $2B peak-year increment management quantified.
Capital deployment cadence: 30+ BD deals since early 2024 has driven the $823M IPR&D expense (5.3% of revenue) this quarter. Watch whether the pace continues and whether any single deal scales toward platform-defining.
Sources
- AbbVie Q2 2025 Press Release, SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm
- AbbVie Q2 2025 earnings call prepared remarks and Q&A (as captured in transcript extraction inputs)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.